Dr Reddys Laboratories vs Takeda Pharmaceutical
RDY and TAK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RDY and TAK compare
Dr Reddys Laboratories grew revenue faster over the last twelve months (3.2% versus −1.7% for Takeda Pharmaceutical).
Dr Reddys Laboratories keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with −3.4% at Takeda Pharmaceutical.
Dr Reddys Laboratories scores higher on the StockData Score (7 against 5 for Takeda Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RDY | TAK |
|---|---|---|
| Size and price | ||
| Share price | $14.17 | $20.91 |
| Change, 1 year | 5.7% | 51.9% |
| Change, 5 years | 11.8% | 46.7% |
| Beta (5Y) | 0.37 | 0.22 |
| Employees | – | 47K |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 3.2% (better) | −1.7% |
| Revenue growth, 5Y average | 12.1% (better) | 7.1% |
| Net income growth (TTM) | −24.2% (better) | −241% |
| EPS growth (TTM) | −24.1% (better) | −244% |
| EPS growth, 5Y average | 19.9% | – |
| Profitability | ||
| Gross margin | 52.8% | 65.1% (better) |
| Operating margin | 15.0% (better) | 0.14% |
| Net margin | 12.8% (better) | −3.4% |
| FCF margin | 10.0% | 19.2% (better) |
| Return on equity | 12.1% (better) | −2.1% |
| Return on invested capital | 9.7% (better) | 0.04% |
| Financial health | ||
| Debt / equity | 0.21 (better) | 0.66 |
| Net debt / EBITDA | 0.87 (better) | 5.89 |
| Interest coverage | 13.5× (better) | 0.0× |
| Current ratio | 1.80 (better) | 1.09 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Payout ratio | 15.5% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 9.9% | – |
| Ownership | ||
| Held by institutions | 15.1% | 6.0% |
| Held by insiders | 13.6% | 0.22% |
| Insider net buying, 12 months | – | −$13.1M |
Go deeper
- RDY stock overview
- RDY income statement
- RDY valuation and score
- TAK stock overview
- TAK income statement
- TAK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.